Periodontitis Stage IIIPhase 1NCT07397026
Clinical and Laboratory Evaluation of Resveratrol Loaded Nanoparticles in the Treatment of Periodontitis: A Randomized Controlled Clinical Trial
A Phase 1 study testing Resveratrol loaded gel in people with Periodontitis Stage III, run by Hagar Ahmed Ali Mohammed Elzain at 1 site in Egypt.
Trial summary
The Aim of this study is to test the effectiveness of locally applied resveratrol as an adjunct to scaling and root planing in the treatment of periodontitis (primary outcome) . Also to assess the level of COX-2 and superoxide dismutase (SOD) in the gingival crevicular fluid samples using the commercially available… Read more about this study
- Who is it for?
- Ages 25 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontitis Stage III
- What is being tested?
- Resveratrol loaded gel
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 48 participants
- Where
- 1 siteEgypt
- Study dates
- 9 Aug 2025to 1 Apr 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adult patient 25-55 years.
- Presence of ≥20 teeth.
- PPD >3\&≤5 mm.
- The patients are in good systemic health.
- Patients have not received any periodontal surgery in the areas that will be assessed in the last 6 months
Who cannot join
- Patients with systemic diseases.
- Pregnant and lactating women.
- Heavy Smokers and tobacco chewers.
- Patients do not follow oral hygiene measures.
- Patients with a known or suspected allergy to any material used in the study.
Trial locations and contacts
1 site in 1 country.
About this study
The Aim of this study is to test the effectiveness of locally applied resveratrol as an adjunct to scaling and root planing in the treatment of periodontitis (primary outcome) . Also to assess the level of COX-2 and superoxide dismutase (SOD) in the gingival crevicular fluid samples using the commercially available kits.
Read the detailed description
Patients who are accepted for this study will be screened by a comprehensive periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017 AAP World Workshop.
- Clinical periodontal parameters, including:
- Plaque Index (PI), according to Silness P. Loe H 1964.
- Gingival Index (GI), according to Silness P. Loe H 1963.
- Eastman Interdental Bleeding Index (EIBI), according to Ainamo \& Bay 1975 .
- Clinical Attachment Level (CAL) is measured from cemento enemal junction to base of the pocket.
- Probing Pocket Depth(PPD) is measured from free gingival margin to base of the pocket. ALL these parameters will be assessed at baseline and after 3 months after treatment for groups 2, 3 and 4 while at baseline only for group 1.
- GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline and after 3 months after treatment for groups 2, 3 and 4 while at baseline only for group 1.
After proper and accurate examination and diagnosis, full mouth supra- and subgingival SRP will be performed with ultrasonic tips and Gracey curettes (Hu-Friedy, Chicago, United States) and an ultrasonic device (Minipiezon, EMS [Electro Medical System], Le Sentier, Switzerland). All patients will receive oral hygiene instructions. After completion of SRP, RES loaded gel will be injected in the selected periodontal pocket of the test group (group 4) while RES unloaded gel will be injected as placebo gel in group 3 using a syringe with a blunt cannula until the pocket will be completely filled.
After atraumatic application of the local drug delivery system, the Patients will be instructed to avoid chewing hard, eating any sticky foods for several hours.
- Conditions
- Periodontitis Stage III
- Being tested
- Resveratrol loaded gel
- Keywords
- Periodontitis, Resveratrol, Nanoparticles, Cox-2, Scaling, root planing, Gingival crevicular fluid, Superoxide dismutase
- Medical subject headings
- Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resveratrol loaded gelDrug
Also called (Resveratrol loaded gel ), Resveratrol Loaded Nanoparticles
Locally injection of Resveratrol Loaded Nanoparticles in patients with stage II periodontitis according to 2017 classification in group 4 only while group 3 will be injected with placebo also group 2 will be treated with only SRP but group 1 is the healthy group ,these participants will only be screened by a comprehensive periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017 AAP World Workshop and no intervention will be done .
| Study group | Role | What they receive |
|---|---|---|
| Group 1 (negative control group): includes 12 periodontally healthy subjects | No intervention | Healthy Patients who are accepted for this study will be screened by a comprehensive periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017 AAP World Workshop. * Clinical periodontal parameters, including: 1. Plaque Index (PI), according to Silness P. Loe H 1964. 2. Gingival Index (GI), according to Silness P. Loe H 1963. 3. Eastman Interdental Bleeding Index (EIBI), according to Ainamo \& Bay 1975. 4. Clinical Attachment Level (CAL) is measured from cemento enemal junction to base of the pocket. 5. Probing Pocket Depth(PPD) is measured from free gingival margin to base of the pocket. ALL these parameters will be assessed at baseline. * GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline . no injection of Resveratrol Loaded Nanoparticles . |
| Group 2(positive control group): includes 12 patients will be treated with Scaling and root planing | Sham comparator | Patients who are accepted for this study will be screened by periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017
* Clinical periodontal parameters, including:
1. Plaque Index (PI) .
2. Gingival Index(GI) .
3. Eastman Interdental Bleeding Index (EIBI) .
4. Clinical Attachment Level (CAL) .
5. Probing Pocket Depth(PPD) is measured from free gingival margin to base of the pocket.
ALL these parameters will be assessed at baseline and after 3 months after treatment .
* GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline and after 3 months after treatment .
After proper and accurate examination and diagnosis, full mouth supra- and subgingival SRP will be performed with ultrasonic tips and Gracey curettes .
patients will receive oral hygiene instructions. Receives: Drug: Resveratrol loaded gel |
| Group 3 (placebo group): includes 12 patients will be treated with Resveratrol unloaded gel | Placebo comparator | Patients who are accepted for this study will be screened by periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017
* Clinical periodontal parameters, including:
1. PI .
2. GI .
3. EIBI .
4. CAL .
5. PPD.
* GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline and after 3 months after treatment .
After diagnosis, full mouth supra- and subgingival SRP will be performed with ultrasonic tips and Gracey curettes .
patients will receive oral hygiene instructions.
After completion of SRP, RES unloaded gel will be injected as placebo gel in using a syringe with a blunt cannula until the pocket will be completely filled.
the Patients will be instructed to avoid chewing hard, eating any sticky foods for several hours.
No intervention of Resveratrol Loaded Nanoparticles . Receives: Drug: Resveratrol loaded gel |
| Group 4 (Resveratrol Loaded Nanoparticles):12 patients will be injected with Resveratrol loaded gel | Other | Patients who are accepted for this study will be screened by periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017
* Clinical periodontal parameters, including:
1. PI .
2. GI .
3. EIBI .
4. CAL .
5. PPD.
* GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline and after 3 months after treatment .
After diagnosis, full mouth supra- and subgingival SRP will be performed with ultrasonic tips and Gracey curettes .
patients will receive oral hygiene instructions.
After completion of SRP, Resveratrol loaded nanoparticles gel will be injected in the selected periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled.
there is intervention by injection of Resveratrol Loaded Nanoparticles inside the pocket . Receives: Drug: Resveratrol loaded gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical attachment level (CAL) as Clinical periodontal parameter
Patients who are accepted for this study will be screened by periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017.
Clinical attachment level (CAL) as Clinical periodontal parameter in mm
Measured: 3 months
Secondary outcomes (1)
laboratory evaluation of Cox-2 & SOD in GCF
GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline and after 3 months after treatment for groups 2, 3 and 4 while at baseline only for group 1.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2026
- Study start9 Aug 2025
- Primary completion1 Mar 2026 (estimated)
- Study completion1 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Periodontitis Stage IIIStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hagar Ahmed Ali Mohammed Elzain
- Sponsor type
- University, hospital or other
- Collaborators
- Mansoura University
- Responsible party
- Sponsor-investigator, Hagar Ahmed Ali Mohammed Elzain, Mansoura University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07397026
- Sponsor's protocol ID
- M0102025OM
- Status last verified
- Feb 2026
- First submitted
- 21 Dec 2025
- Last updated
- 9 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Kornman KS. Controlled-Release Local Delivery Antimicrobials in Periodontics: Prospects for the Future. J Periodontol. 1993 Aug;64 Suppl 8S:782-791. doi: 10.1902/jop.1993.64.8s.782.
PubMed 29539751Goodson JM, Haffajee A, Socransky SS. Periodontal therapy by local delivery of tetracycline. J Clin Periodontol. 1979 Apr;6(2):83-92. doi: 10.1111/j.1600-051x.1979.tb02186.x.
PubMed 379050Cobb CM. Clinical significance of non-surgical periodontal therapy: an evidence-based perspective of scaling and root planing. J Clin Periodontol. 2002 May;29 Suppl 2:6-16.
PubMed 12010523Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction. Periodontol 2000. 1997 Jun;14:9-11. doi: 10.1111/j.1600-0757.1997.tb00189.x. No abstract available.
PubMed 9567963Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol. 2003 Mar;74(3):391-401. doi: 10.1902/jop.2003.74.3.391.
PubMed 12710761Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol. 2010 Jul;8(7):481-90. doi: 10.1038/nrmicro2337.
PubMed 20514045Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015 Jan;15(1):30-44. doi: 10.1038/nri3785.
PubMed 25534621Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000. 2002;28:12-55. doi: 10.1034/j.1600-0757.2002.280102.x. No abstract available.
PubMed 120133401. Hussein MH, Badr BM, Hassan KS, Ibrahim IH. Evaluation of the Effect of Topically Applied Resveratrol Gel as Adjunctive Treatment for Periodontitis. European Journal of General Dentistry. 2024.
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical and Laboratory Evaluation of Resveratrol Loaded Nanoparticles in the Treatment of Periodontitis: A Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT07397026
- Acronym / sponsor ID
- M0102025OM
- Conditions
- Periodontitis Stage III
- Keywords
- Periodontitis, Resveratrol, Nanoparticles, Cox-2, Scaling, root planing, Gingival crevicular fluid, Superoxide dismutase
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Hagar Ahmed Ali Mohammed ElzainUniversity, hospital or other
- Collaborators
- Mansoura University
- Study start
- 9 Aug 2025 (actual)
- Primary completion
- 1 Mar 2026 (estimated)
- Study completion
- 1 Apr 2026 (estimated)
- First posted
- 9 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Aim of this study is to test the effectiveness of locally applied resveratrol as an adjunct to scaling and root planing in the treatment of periodontitis (primary outcome) . Also to assess the level of COX-2 and superoxide dismutase (SOD) in the gingival crevicular fluid samples using the commercially available kits.
Detailed description
Patients who are accepted for this study will be screened by a comprehensive periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017 AAP World Workshop.
- Clinical periodontal parameters, including:
- Plaque Index (PI), according to Silness P. Loe H 1964.
- Gingival Index (GI), according to Silness P. Loe H 1963.
- Eastman Interdental Bleeding Index (EIBI), according to Ainamo \& Bay 1975 .
- Clinical Attachment Level (CAL) is measured from cemento enemal junction to base of the pocket.
- Probing Pocket Depth(PPD) is measured from free gingival margin to base of the pocket. ALL these parameters will be assessed at baseline and after 3 months after treatment for groups 2, 3 and 4 while at baseline only for group 1.
- GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline and after 3 months after treatment for groups 2, 3 and 4 while at baseline only for group 1.
After proper and accurate examination and diagnosis, full mouth supra- and subgingival SRP will be performed with ultrasonic tips and Gracey curettes (Hu-Friedy, Chicago, United States) and an ultrasonic device (Minipiezon, EMS [Electro Medical System], Le Sentier, Switzerland). All patients will receive oral hygiene instructions. After completion of SRP, RES loaded gel will be injected in the selected periodontal pocket of the test group (group 4) while RES unloaded gel will be injected as placebo gel in group 3 using a syringe with a blunt cannula until the pocket will be completely filled.
After atraumatic application of the local drug delivery system, the Patients will be instructed to avoid chewing hard, eating any sticky foods for several hours.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group 1 (negative control group): includes 12 periodontally healthy subjects | No intervention | –Healthy Patients who are accepted for this study will be screened by a comprehensive periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017 AAP World Workshop. * Clinical periodontal parameters, including: 1. Plaque Index (PI), according to Silness P. Loe H 1964. 2. Gingival Index (GI), according to Silness P. Loe H 1963. 3. Eastman Interdental Bleeding Index (EIBI), according to Ainamo \& Bay 1975. 4. Clinical Attachment Level (CAL) is measured from cemento enemal junction to base of the pocket. 5. Probing Pocket Depth(PPD) is measured from free gingival margin to base of the pocket. ALL these parameters will be assessed at baseline. * GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline . no injection of Resveratrol Loaded Nanoparticles . |
| Group 2(positive control group): includes 12 patients will be treated with Scaling and root planing | Sham comparator | Drug: Resveratrol loaded gelPatients who are accepted for this study will be screened by periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017 * Clinical periodontal parameters, including: 1. Plaque Index (PI) . 2. Gingival Index(GI) . 3. Eastman Interdental Bleeding Index (EIBI) . 4. Clinical Attachment Level (CAL) . 5. Probing Pocket Depth(PPD) is measured from free gingival margin to base of the pocket. ALL these parameters will be assessed at baseline and after 3 months after treatment . * GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline and after 3 months after treatment . After proper and accurate examination and diagnosis, full mouth supra- and subgingival SRP will be performed with ultrasonic tips and Gracey curettes . patients will receive oral hygiene instructions. |
| Group 3 (placebo group): includes 12 patients will be treated with Resveratrol unloaded gel | Placebo comparator | Drug: Resveratrol loaded gelPatients who are accepted for this study will be screened by periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017 * Clinical periodontal parameters, including: 1. PI . 2. GI . 3. EIBI . 4. CAL . 5. PPD. * GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline and after 3 months after treatment . After diagnosis, full mouth supra- and subgingival SRP will be performed with ultrasonic tips and Gracey curettes . patients will receive oral hygiene instructions. After completion of SRP, RES unloaded gel will be injected as placebo gel in using a syringe with a blunt cannula until the pocket will be completely filled. the Patients will be instructed to avoid chewing hard, eating any sticky foods for several hours. No intervention of Resveratrol Loaded Nanoparticles . |
| Group 4 (Resveratrol Loaded Nanoparticles):12 patients will be injected with Resveratrol loaded gel | Other | Drug: Resveratrol loaded gelPatients who are accepted for this study will be screened by periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017 * Clinical periodontal parameters, including: 1. PI . 2. GI . 3. EIBI . 4. CAL . 5. PPD. * GCF samples will be collected using sterile paper strips and analyzed using the commercially available kits for the assessment of the level of COX-2 and SOD at baseline and after 3 months after treatment . After diagnosis, full mouth supra- and subgingival SRP will be performed with ultrasonic tips and Gracey curettes . patients will receive oral hygiene instructions. After completion of SRP, Resveratrol loaded nanoparticles gel will be injected in the selected periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. there is intervention by injection of Resveratrol Loaded Nanoparticles inside the pocket . |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Adult patient 25-55 years.
- Presence of ≥20 teeth.
- PPD >3\&≤5 mm.
- The patients are in good systemic health.
- Patients have not received any periodontal surgery in the areas that will be assessed in the last 6 months
Key exclusion criteria (5 listed)
- Patients with systemic diseases.
- Pregnant and lactating women.
- Heavy Smokers and tobacco chewers.
- Patients do not follow oral hygiene measures.
- Patients with a known or suspected allergy to any material used in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resveratrol loaded gelAlso: (Resveratrol loaded gel ), Resveratrol Loaded NanoparticlesLocally injection of Resveratrol Loaded Nanoparticles in patients with stage II periodontitis according to 2017 classification in group 4 only while group 3 will be injected with placebo also group 2 will be treated with only SRP but group 1 is the healthy group ,these participants will only be screened by a comprehensive periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017 AAP World Workshop and no intervention will be done . | Drug | Group 2(positive control group): includes 12 patients will be treated with Scaling and root planing, Group 3 (placebo group): includes 12 patients will be treated with Resveratrol unloaded gel, Group 4 (Resveratrol Loaded Nanoparticles):12 patients will be injected with Resveratrol loaded gel |
Primary outcome
Clinical attachment level (CAL) as Clinical periodontal parameter
Time frame: 3 months
Patients who are accepted for this study will be screened by periodontal examination and full periodontal charts. Proper Diagnosis of the stages of periodontitis will be based on the new classification proposed in 2017. Clinical attachment level (CAL) as Clinical periodontal parameter in mm
1 secondary outcome
laboratory evaluation of Cox-2 & SOD in GCF
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
- Background: PubMed 29539751Kornman KS. Controlled-Release Local Delivery Antimicrobials in Periodontics: Prospects for the Future. J Periodontol. 1993 Aug;64 Suppl 8S:782-791. doi: 10.1902/jop.1993.64.8s.782.
- Background: PubMed 379050Goodson JM, Haffajee A, Socransky SS. Periodontal therapy by local delivery of tetracycline. J Clin Periodontol. 1979 Apr;6(2):83-92. doi: 10.1111/j.1600-051x.1979.tb02186.x.
- Background: PubMed 12010523Cobb CM. Clinical significance of non-surgical periodontal therapy: an evidence-based perspective of scaling and root planing. J Clin Periodontol. 2002 May;29 Suppl 2:6-16.
- Background: PubMed 9567963Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction. Periodontol 2000. 1997 Jun;14:9-11. doi: 10.1111/j.1600-0757.1997.tb00189.x. No abstract available.
- Background: PubMed 12710761Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol. 2003 Mar;74(3):391-401. doi: 10.1902/jop.2003.74.3.391.
- Background: PubMed 20514045Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol. 2010 Jul;8(7):481-90. doi: 10.1038/nrmicro2337.
- Background: PubMed 25534621Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015 Jan;15(1):30-44. doi: 10.1038/nri3785.
- Background: PubMed 12013340Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000. 2002;28:12-55. doi: 10.1034/j.1600-0757.2002.280102.x. No abstract available.
- Background1. Hussein MH, Badr BM, Hassan KS, Ibrahim IH. Evaluation of the Effect of Topically Applied Resveratrol Gel as Adjunctive Treatment for Periodontitis. European Journal of General Dentistry. 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Periodontitis Stage III
RecruitingObservational study
Characterization of Small Intestinal Bacterial Overgrowth and Intestinal Barrier-Related Biomarkers in Patients With Severe Periodontitis
Periodontitis (Stage 3), Periodontitis Stage IV
Recruiting
A Clinical Trial Comparing 2x/Day for 30-minutes Use of the Emanate Perio PODS Post-SRP to a Control Group Post-SRP.
Periodontitis (Stage 3)
Active, not recruitingObservational study
Evaluation of the Effect of Smoking on Apelin, Periostin, and High-Sensitivity CRP Levels in Gingival Crevicular Fluid and Serum
Periodontitis (Stage 3), Periodontal Health
Recruiting
Active Oxygen Releasing Gel With Photodynamic Therapy in Treating Stage III Periodontitis
Stage III Periodontitis
Recruiting
Dental Loupe Versus Dental Operating Microscope for Non-Surgical Periodontal Treatment
Periodontitis, Periodontitis and Treatment Need
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Resveratrol loaded gel in people with Periodontitis Stage III, run by Hagar Ahmed Ali Mohammed Elzain at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical attachment level (CAL) as Clinical periodontal parameter (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07397026, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.